GeneDx HoldingsWGS
Recorded

GeneDx Holdings 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration51 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please be advised that today's call is being recorded. I would now like to hand it over to our first speaker, Sabrina Dunbar. Investor relations, please go ahead.

Sabrina DunbarDirector of Investor Relations and Communications

Thank you, operator, and thank you everyone for joining us today. On the call, we have Katherine Stueland, Chief Executive Officer, Kevin Feeley, Chief Financial Officer, and Mark Gardner, President. Earlier today, GeneDx released financial results for the third quarter ended September 30, 2026. Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today's call, including about our business plans, 2026 guidance, and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, November 9, and we are under no obligation to update. When discussing our results, we refer to non-GAAP measures, which exclude certain items from reported results. Please refer to our third quarter 2026 earnings release and slides available at ir.genedx.com for definitions and reconciliations of non-GAAP measures and additional information regarding our results.

Sabrina DunbarDirector of Investor Relations and Communications

Additionally, please refer to our most recent annual and quarterly filings with the SEC for a discussion of factors that could cause actual results to materially differ from forward-looking statements. With that, I'll turn the call over to Catherine.

Katherine StuelandCEO

Thanks, Sabrina, and good afternoon, everyone. Our Q3 results reflect profitable execution in a growing market. As we first shared in May, we've organized our business around three key imperatives, and in Q3, we made concerted progress on each of them. First and foremost, optimizing unit economics, second, growing utilization, and third, delivering leading products at unmatched scale, all while managing capital responsibly. Today, I'll discuss the highlights of our quarter. Mark will provide a deeper dive on our RCM and commercial initiatives, and Kevin will walk us through the financials. In the third quarter, we reported $123.1 million in total revenue, expanded adjusted gross margin to 72%, generated adjusted net income of $8.6 million, and resulted over 32,100 exome and genome tests. In Q2, we shared that RCM was our number one priority, and we're pleased with the progress we saw here.

Katherine StuelandCEO

Our average reimbursement rate increased approximately 5% sequentially, reflecting both improved genome collections and mix shift into our exome line. As we prioritize profitable growth, we are raising gross margin and net income guidance and reaffirming our full-year total revenue guidance. To that end, in Q3, we aligned genome testing workflows to collect more payer-required documentation before testing begins in the lab. We evaluated the potential effects on ARR, volume, and total revenue and deliberately prioritized a more sustainable path to payment, leading to a sequential step-up in ARR. As we implement these processes and educate clinicians on payer requirements, we are adjusting our volume expectations to give these workflows more time to mature. As a market leader, we are building a better model, one that prioritizes profitable growth, thus enabling us to reinvest into our patients, our products, and our operations in a self-sustaining way.

Katherine StuelandCEO

Part of that model is working closely with payers and governments to ensure equitable, sustainable access to whole exome and genome testing. To support those efforts, I am excited to welcome Nicole Maassen as Chief Patient Access Officer. Nicole was a pivotal force in transforming the market access strategy during her time at Exact Sciences, and as part of our team, she will advance our payer partnerships, build upon our government relations efforts, and help translate positive coverage policies into timely access for children who need testing. Demand is strong. We saw growth across all markets in Q3 as clinicians continue to choose GeneDx for our reliability, quality, and customer experience. This quarter, we made genomic testing easier to adopt with new ordering features, simplified reports, and post-test guides. These enhancements, together with expanded EHR capabilities, support broader adoption of exome and genome across care settings.

Katherine StuelandCEO

We also advanced product innovation in the quarter. We continue to believe genome sequencing will become the standard for diagnosing heritable disease, and our ambition is clear: to consistently deliver the number one genome on the market. We recently announced the inclusion of long-read sequencing as part of our genome portfolio, and we expect to continue rolling out new technologies over the coming quarters. Our underlying data asset, GeneDx Infinity™, underpins many of our competitive advantages in the exome and genome testing markets, but its value also extends beyond our core diagnostics business. Our biopharma and data business grew for the second consecutive quarter, with Mirum Pharmaceuticals and Beren Therapeutics joining our portfolio of sponsored testing partners. In tandem, we are seeing increasing interest from AI and ML and technology players in how our data can advance drug discovery and precision medicine. This is our long-term value proposition coming to life.

Katherine StuelandCEO

As we diagnose more patients, we improve our interpretation capabilities, turn diagnoses into therapeutic breakthroughs, and unlock new avenues for growth and patient impact. With that, I will pass the call over to Mark.

Mark GardnerPresident

Thank you, Catherine, and good afternoon, everyone. Our remarks today will focus on collections and commercial execution. A genetic test that ends the diagnostic odyssey has real value, and we're intent on getting paid for the value we deliver. Sadly, it has been a common practice of the lab services industry to perform testing in as frictionless a way as possible, to grow volume without regard for whether a test will be paid for or not. We are committed to defending this value for the long term. Our commitments to our patients, clinicians, and shareholders are too important to perpetuate these volume-at-all-cost tactics, particularly because we're in the early stages of penetrating this growing market. The opportunity I saw when I joined GeneDx remains clear. We have strong demand and differentiated clinical capabilities.

Mark GardnerPresident

Now we must match those strengths with more consistent operational execution to convert unexplained symptoms into orders more consistently, move orders into actionable reports more efficiently, and turn reports into reimbursement more effectively. We started a multi-year revenue cycle transformation. We're in the early stages, but we improved all three of the key metrics that we shared last quarter. Kevin will walk through those details in a moment, but we expect most improvements to impact 2027 and beyond as we continue to tackle our list of RCM initiatives and progress towards collection rates in line with industry norms. We deeply interrogated the root causes of our exome and genome denials, and we found that 62% of them were administrative and procedural in nature. These are addressable with time, effort, and execution, and this is where our team is dedicating most of our immediate efforts.

Mark GardnerPresident

The remaining 38% relate to subjective clinical necessity disputes or to patients who are not covered by payor policies, and we'll address this group over time. One of the most impactful actions we can take to improve our collection rate is to collect better documentation upfront. As Catherine shared, in Q3, we aligned genome testing workflows to collect more payor-required documentation before testing begins in the lab. Collecting documentation upfront can extend the time between accession and the start of testing, as indicated by accessions growing 28%, while reported volume grew 25% in the quarter. That friction resulted in higher rates of order cancellations, downgrades, and delayed starts.

Mark GardnerPresident

While that creates a near-term headwind to reported volume, we believe that this is the right approach to support durable revenue growth and expect these requirements to become easier for clinicians to navigate as we implement additional AI and technology tools into our RCM processes. Next, let me speak to how our commercial strategy is enabling us to keep driving demand across core and emerging call points. Our core markets of geneticists and pediatric neurologists delivered strong growth in the quarter, primarily through increased productivity per clinician. We remain the market leader in these segments, and we continue to invest significantly in product development, key opinion leader collaborations, and electronic medical record connectivity to deepen our relationships with these customers. In our emerging markets, we are seeing our commercial investments from early in the year come to fruition.

Mark GardnerPresident

Importantly, the general pediatrician segment is poised to drive greater unit volume growth in 2027 than all other segments. The GenPeds team entered the field in February, and following two quarters of ramp-up, they're already paying for themselves. Clinicians are placing repeat orders and sharing positive feedback on our enhanced customer ordering experience, and both of these give us confidence moving forward. Lastly, I want to go deeper on something Catherine already referenced, which is the value of GeneDx Infinity™ for building durable competitive differentiation. Many rare pediatric diseases are caused by de novo variants, which arise in the child and are not inherited from either parent. These variants are often seen in only a handful of patients worldwide, and they rarely appear in published literature.

Mark GardnerPresident

The only way to interpret them is with experience, and GeneDx has sequenced more of these variants than anyone else by an order of magnitude. As we add technologies like long-read sequencing to our portfolio, we can both measure more variants but also expertly match one patient's genetic and clinical profile with another's, thus confirming a genetic diagnosis. That matching exercise is unique, it is cumulative, and it compounds over time. I'll now pass it to Kevin to walk through our financial results.

Kevin FeeleyCFO

Thanks, Mark, and good afternoon, everyone. Third quarter 2026 total revenues were $123.1 million, inclusive of $110.4 million of exome genome revenues, which is up $10 million sequentially. This sequential growth is the right frame for evaluating our trajectory, with continued growth and financial improvement. Adjusted gross margin expanded from 69% in Q1 to 70% in Q2 and 72% in Q3, and adjusted net income improved from an $8.2 million loss in Q1 to near break-even in Q2 to $8.6 million this quarter, two consecutive quarters of improvement with more to come. Our blended average reimbursement rate in the third quarter was $3,436, up 5% from $3,258 in the second quarter. We're guiding to another step up in Q4, and we believe the trajectory continues from there as our revenue cycle work matures.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day